Design of zinc binding functions for carbonic anhydrase inhibitors

Current Pharmaceutical Design

Volumn 14, Issue 7, 2008, Pages 615-621

  Winum, Jean Yves ^a   Scozzafava, Andrea ^b   Montero, Jean Louis ^a   Supuran, Claudiu T ^b  

^a INSTITUT CHARLES GERHARDT   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETOHYDROXAMIC ACID; BICARBONATE; CARBON DIOXIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE ACTIVATOR; CARBONATE DEHYDRATASE INHIBITOR; ENZYME ACTIVATOR; FOSCARNET; HYDROXYUREA; ISOENZYME; MEDRONIC ACID; METALLOPROTEIN; METHYLPHOSPHONIC ACID; PHOSPHOSERINE; PHOSPHOTHREONINE; PROTON; SPARFOSIC ACID; SULFANILAMIDE; SULFONAMIDE; TOPIRAMATE; ZINC ION; ZINC;

BINDING KINETICS; DRUG DESIGN; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME MECHANISM; EYE DISEASE; HYDRATION; MALIGNANT NEOPLASTIC DISEASE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VERTEBRATE; X RAY CRYSTALLOGRAPHY; ANIMAL; BINDING SITE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BINDING SITES; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG DESIGN; HUMANS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

EID: 42149127006     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783877848     Document Type: Review

References (36)

1. The Biological Chemistry of the Elements. The Inorganic Chemistry of Life, Frausto da Silva JJR, Williams RJP, Eds., 2nd ed., Oxford University Press, New York, 2001.
2. (a) Hernick M, Fierke, CA. Zinc hydrolases: The mechanisms of zinc-dependent deacetylases. Arch Biochem Biophvs 2005; 433: 71-84.
3. (b) Vallee BL, Auld DS. Zinc: Biological functions and coordination motifs. Acc Chem Res 1993; 26: 543-51.
4. (c) Vallee BL, Auld, DS. Zinc coordination, function and structure of zinc enzyme and other proteins. Biochemistry 1990; 29: 5647-59.
5. (a) Parkin G. Synthetic analogues relevant to the structure and function of zinc enzymes. Chem Rev 2004; 104: 699-767.
6. (b) Lipscomb WN, Sträter N. Recent advances in zinc enzymology. Chem Rev 1996; 96: 2375-2433.
7. (a) Nuti E, Tuccinardi T, Rossello A. Matrix metalloproteinase inhibitors: New challenges in the area of post broad-spectrum inhibitors. Curr Pharm Des 2007; 13: 2087-100.
8. (b) Supuran CT, Scozzafava A. Matrix metalloproteinases (MMPs). In Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development, Smith HJ, Simons C, Eds., Taylor & Francis, London & New York, pp. 35-61, 2002.
9. a) Carbonic anhydrase - Its Inhibitors and Activators; Supuran CT, Scozzafava A, Conway J, Eds.; CRC Press: Boca Raton, London, New York, 2004.
10. (b) Supuran CT, Scozzalava A, Casini A. Carbonic anhydrase, inhibitors. Med Res Rev 9003; 23: 146-89.
11. (a) Supuran CT. Carbonic anhydrase: Novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 2008; 7: 168-181.
12. (b) Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors, and activators and their use in therapy Expert Opin Ther Patents 2006; 16: 1627-64.
13. (a) Supuran CT. Carbonic anhydrases as drug targets-an overview. CurrTop Med Chem 2007; 7: 825-33.
14. (b) Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007; 15: 4336-50.
15. (a) Winum JY, Scozzafava A, Montero Jl, Supuran CT. Sulfamates and their therapeutic potential Med Res Rev 2005; 25: 186-228.
16. (b) Winum JY, Scozzafava A, Montero JL, Supuran CT. Therapeutic potential of sulfamides of enzyme inhibitors. Med Res Rev 2006; 26: 767-792.
17. Winum JY, Scozzafava A, Montero JL, Supuran CT. Therapeutic applications of sulfamates. Expert Opin Ther Patents 2004; 14: 1273-1308.
18. Winum JY, Scozzafava A, Montero JL, Supuran CT. The sulfamide motif in the design of enzyme inhibitors. Expert Opin Ther Patents 2004; 16: 27-47.
19. Winum JY, Scozzafava A, Montero JL, Suporan CT. Metal binding functions in the design of carbonic anhydrase inhibitors. Curr Top Med Chem 2007; 7: 835-48.
20. Fenesan I, Popescu R, Scozzafava A, Crucin V, Mateiciue E, Bauer R, et al. Carbonic anhydrase inhibitors. Phosphoryl sulfonamides. A new class of high affinity inhibitors of isozyme I. J Enz Inhib 2000; 15: 297-310.
21. Krebs HA. Inhibitors of carbonic anhydrase by sulfonamides. Biochem J 1948; 43: 525-29.
22. Mincione F, Menabuoni L, Briganti F, Mincione G, Scozzafava A. Supuran CT. Carbonic anhydrase inhibitors. Inhibition of isoozymes I, II and IV with N-hydroxysulfonamides. A novel class of intraocular pressure lowering agents. J Enz Inhib 1998; 13: 267-284.
23. Supuran CT, Scozzafava A, Briganti F. Carbonic anhydrase inhibitors: N-cyanosulfonamides: A new class of high affinity isozyme II and IV inhibitors. J Enz Inhib 1999; 14: 289-306.
24. Scozzafava A, Banciu MD, Popescu A, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of isozymes I, II and IV by sulfamide and sulfamic acid derivatives. J Enz Inhib 2000; 15: 443-53.
25. Bonnac L, Innocenti A, Winum JY, Casini A, Montero JL, Scozzafava A, et al. Carbonic anhydrase inhibitors: Aliphatic N-phosphorylated sulfamate. A novel zinc anchoring group leading to nanomolar inhibitors. J Enz Inhib Med Chem 2004; 19: 287-91.
26. Rusconi S, Innocenti A, Vullo D, Mastrolorenzo A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V and IX with phosphates, carbamoyl phosphate phate, and the phosphonate antiviral drug foscarnet. Bioorg Med Chem Lett 2004; 14: 5763-67.
27. Temperini C, Innocenti A, Guerri A, Scozzafava A, Rusconi S, Supuran CT. Phosph(on)ate as a zinc binding group in metalloenzyme inhibitors. X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorg Med Chem Lett 2007; 17: 5763-67.
28. Winum JY, Temperini C, El Cheikh K, Innocenti A, Vullo D, Ciattini S, et al. Carbonic anhydrase inhibitors: Clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006; 49: 7024-31.
29. Winum JY, Innocenti A, Gagnard V, Montero JL, Scozzafava A, Vullo D, et al. Carbonic anhydrase inhibitors. Interaction of isozymes I, UU, IV, V and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett 2005; 15: 1683-86.
30. Scolnick LR, Clements AM, Liao J, Crenshaw L, Hellberg M, May J, et al. Novel Binding Mode of Hydroxamate Inhibitors to Human Carbonic Anhydrase II. J Am Chem Soc 1997; 119: 850-51.
31. Scozzafava A, Supuran CT. Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg Med Chem 2003; 11: 2241-46.
32. Temperini C, Innocenti A, Scozzafava A, Supuran CT. N-hydroxyurea-A versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett 2006; 16: 4316-20.
33. Briganti F, Pierattelli A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigation on native and cobalt-substituted enzymes. Eur J Med Chem 1996; 31: 1001-10.
34. Abbate F, Supuran CT, Scozzafava A, Orioli P, Stubbs MT, Klebe G. Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: Role of hydrogen-bonding networks in ligand binding qnd drug design. J Med Chem 2002; 45: 3583-87.
35. Temperini C, Winum JY, Montero JL, Scozzafava A, Supuran CT. Carbonic annydrase inhibitors. The X-ray crystal structure of the adduct of N-hydroxysulfamide with the isozyme II explains why this new zinc binding function is effective in the design of potent inhibitors. Bioorg Med Chem Lett 2007; 17: 2797-2801.
36. Winum JY, Innocenti A, Nasr J, Montero JL, Scozzafava A, Vullo D, et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamides - A new zinc-binding function in the design of inhibitors. Bioorg Med Chem Lett 2005: 15: 2353-58.